• SENSEX 82,104.79
    512.34 (+0.63%)
  • BANKNIFTY 61,575.90
    541.80 (+0.89%)
Back

Results - Announcements

Glenmark Pharmaceuticals Ltd consolidated sales up 5.73% on year in Q3FY2026
06-Nov-2026, 10:55

Glenmark Pharmaceuticals Ltd share price declined by 0.65% to Rs 2485.5 after the company's net profit tumbled by 45.36% to Rs 263.83 crore, while revenue from operations improved marginally 5.73% to Rs 4157.09 crore in Q3FY26 over Q2FY26.


The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.09%. It has improved by 2.18% over last one week and ticked higher by 2.72% in last one month while the market capitalization of Glenmark Pharmaceuticals Ltd has inched up 7.69% and 8.69% in the same period respectively.


Profit before tax (PBT) of Glenmark Pharmaceuticals Ltd stood at Rs 338.29 crore in Q3 FY26, tanking 65.03% year-on-year, and tumbling by 47.42% quarter-on-quarter. EBITDA came in at Rs 861 crore, plunging by 60.11% YoY and surging by 16.54% sequentially.


Total expenses grew marginally by 5.23% to Rs 3563.94 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 837.88 crore, jumping 39.40% YoY, while employee benefits expense was at Rs 1027.64 crore, expanding by 9.94% YoY.


For the TTM ended FY26, revenue from operations surged 27.12% to Rs 16711.4 crore, while net profit saw a strong growth of 30.06% to Rs 1361.95 crore, compared to previous TTM. EBITDA jumped by 232413% to Rs 4111.8 crore, and PBT jumped 41.85% to Rs 1984.75 crore compared to previous TTM.


The company's consolidated net cash flow from operating activities stood at Rs 3445.03 crore in FY26, as against Rs 827.6 crore in FY25.


Glenmark Pharmaceuticals Ltd surged by 37.27% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 4.80% during the same period.